Skip to content
10-Q

Quarterly Report

Olema Pharmaceuticals, Inc. OLMA

0001193125-26-218156

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 87.35M sh
Shares Diluted Q1 2026 · Mar 31, 2026 102.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 85.43M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$45.99M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$43.98M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $52.55M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $48.3M
Stockholders Equity Q1 2026 · Mar 31, 2026 $480.48M
Stockholders Equity Q1 2026 · Dec 31, 2025 $478.56M
Stockholders Equity Q1 2026 · Mar 31, 2025 $383.45M
Stockholders Equity Q1 2026 · Dec 31, 2024 $408.96M
Current Liabilities Q1 2026 · Mar 31, 2026 $47.17M
Current Liabilities Q1 2026 · Dec 31, 2025 $51.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $50.17M
Total Liabilities Q1 2026 · Dec 31, 2025 $54.87M
Current Assets Q1 2026 · Mar 31, 2026 $513.23M
Current Assets Q1 2026 · Dec 31, 2025 $515.45M
Total Assets Q1 2026 · Mar 31, 2026 $530.65M
Total Assets Q1 2026 · Dec 31, 2025 $533.43M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.52
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.36
Eps Basic Q1 2026 · Mar 31, 2026 −$0.52
Eps Basic Q1 2026 · Mar 31, 2025 −$0.36
Sga Expense Q1 2026 · Mar 31, 2026 $8.75M
Sga Expense Q1 2026 · Mar 31, 2025 $4.25M
Rd Expense Q1 2026 · Mar 31, 2026 $49.23M
Rd Expense Q1 2026 · Mar 31, 2025 $30.62M
Net Income Q1 2026 · Mar 31, 2026 −$53.09M
Net Income Q1 2026 · Mar 31, 2025 −$30.39M
Operating Income Q1 2026 · Mar 31, 2026 −$57.99M
Operating Income Q1 2026 · Mar 31, 2025 −$34.87M